Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 01 Aug 2023
Global sarcoma therapy now listed on Pharmaceutical Benefits Scheme
31 July 2023 - Yondelis (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine. ...
Posted by Michael Wonder on 01 Aug 2023
China’s National Medical Products Administration accepts Astellas’ biologics license application for zolbetuximab
31 July 2023 - Astellas Pharma today announced that the Center for Drug Evaluation of the China National Medical Products Administration ...
Posted by Michael Wonder on 01 Aug 2023
Stakeholders want clearer terms in FDA's generally accepted scientific knowledge guidance
31 July 2023 - Drug makers and research groups are generally supportive of the US FDA’s plan to allow greater flexibility ...
Posted by Michael Wonder on 31 Jul 2023
CMS releases 2024 projected Medicare Part D premium and bid information
31 July 2023 - The CMS today announced that the average total monthly premium for Medicare Part D coverage is projected ...
Posted by Michael Wonder on 31 Jul 2023
Drug makers go under the skin, skirting early US Medicare price negotiations
28 July 2023 - Injectable versions of some widely-used cancer drugs including Johnson & Johnson's blockbuster multiple myeloma treatment Darzalex ...
Posted by Michael Wonder on 31 Jul 2023
FDA approves dostarlimab-gxly with chemotherapy for endometrial cancer
31 July 2023 - Today, the FDA approved dostarlimab-gxly (Jemperli, GlaxoSmithKline) with carboplatin and paclitaxel, followed by single-agent dostarlimab-gxly, for ...
Posted by Michael Wonder on 31 Jul 2023
Fair allocation of scarce CAR T-cell therapies for relapsed/refractory multiple myeloma
31 July 2023 - The treatment landscape for relapsed/refractory multiple myeloma has undergone an immunotherapeutic breakthrough with the introduction of ...
Posted by Michael Wonder on 31 Jul 2023
Schedule of Pharmaceutical Benefits - 1 August 2023
1 August 2023 - The August 2023 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Jul 2023
Bavencio gets coverage as first-line maintenance therapy for urothelial cancer
25 July 2023 - Merck’s anti-PD-L1 immuno-oncology drug Bavencio (avelumab) will get insurance coverage starting next month as first-line maintenance ...
Posted by Michael Wonder on 31 Jul 2023
New Zealand Pharmaceutical Schedule - 1 August 2023
1 August 2023 - The August 2023 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Jul 2023
International harmonisation of ingredient names - changes to the PBS Schedule effective 1 August 2023
PBAC - The PBS Schedule has been updated in the 1 August 2023 Schedule to show sole ingredient names for ...
Posted by Michael Wonder on 31 Jul 2023
FDA grants fast track designation to IVS-3001, a CAR-T cell therapy in the treatment of renal cell carcinoma
31 July 2023 - Invectys is pleased to announce the US FDA has granted fast track designation to its revolutionary ...
Posted by Michael Wonder on 31 Jul 2023
US FDA accepts biologics license application for GC Biopharma's GC5107B (immune globulin intravenous (human), 10% liquid)
31 July 2023 - GC Biopharma today announced that the US FDA has accepted the Company's resubmission of the biologics ...
Posted by Michael Wonder on 30 Jul 2023
PHARMAC’s funding model creating an ‘ethical dilemma’ - specialist
29 July 2023 - The New Zealand Breast Cancer Foundation is renewing calls for PHARMAC to fund Keytruda for the ...
Posted by Michael Wonder on 30 Jul 2023
Citius Pharmaceuticals receives a complete response letter from the US FDA for Lymphir (denileukin diftitox) for the treatment of patients with relapsed or refractory cutaneous T-cell lymphoma
29 July 2023 - No clinical efficacy or safety issues raised. ...